Wide Ranks

GKOS

Glaukos Corporation

142.69

Top Statistics
Market Cap 7 B Forward PE -130.80 Revenue Growth 23.90 %
Current Ratio 5.54 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -41.51 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -96.21 Enterprise / Revenue 21.54 Price To Sales Trailing12 Months 21.83
Profitability
Profit Margins -41.51 % Operating Margins -25.51 %
Balance Sheet
Total Cash 262 M Total Cash Per Share 4.76 Total Debt 159 M
Total Debt To Equity 23.90 Current Ratio 5.54 Book Value Per Share 12.13
All Measures
Short Ratio 497.00 % Message Board Id finmb_3131592 Fax 949 367 9984
Shares Short Prior Month 2 M Return On Equity -0.2610 City Aliso Viejo
Uuid 31342110-c926-373b-8780-60d68478ea6f Previous Close 140.73 First Trade Date Epoch Utc 1 B
Book Value 12.13 Beta 1.03 Total Debt 159 M
Volume 348798 Price To Book 11.76 Fifty Two Week Low 59.58
Total Cash Per Share 4.76 Total Revenue 360 M Shares Short Previous Month Date 1 B
Target Median Price 145.00 Max Age 86400 Recommendation Mean 1.79
Sand P52 Week Change 0.3133 Operating Margins -25.51 % Target Mean Price 142.42
Net Income To Common -149571008 Ask 147.21 Short Percent Of Float 0.0817
Implied Shares Outstanding 55 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 431120 Average Volume10days 431120 Total Cash 262 M
Next Fiscal Year End 1 B Revenue Per Share 7.06 Held Percent Insiders 0.0319
Ebitda Margins -22.39 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 140.73 Target Low Price 115.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 133.58 Open 141.75
Free Cashflow -30490124 State CA Dividend Yield 0.00 %
Return On Assets -0.0774 Time Zone Short Name EST Trailing Eps -2.93
Day Low 141.56 Address1 One Glaukos Way Shares Outstanding 55 M
Price Hint 2 Target High Price 162.00 Website https://www.glaukos.com
52 Week Change 1.23 Average Volume 532743 Forward Eps -1.10
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 444.80 %
Is_sp_500 False Regular Market Day High 144.51 Profit Margins -41.51 %
Debt To Equity 23.90 Fifty Two Week High 146.86 Day High 144.51
Shares Short 2 M Regular Market Open 141.75 Industry Key medical-devices
Bid 139.02 Earnings Growth 0.00 % Enterprise To Revenue 21.54
Revenue Growth 23.90 % Shares Percent Shares Out 0.0510 Operating Cashflow -72490000
Currency USD Time Zone Full Name America/New_York Market Cap 7 B
Is_nasdaq_100 False Zip 92656 Quote Type EQUITY
Industry Medical Devices Long Name Glaukos Corporation Regular Market Day Low 141.56
Held Percent Institutions 1.01 Current Price 142.69 Enterprise To Ebitda -96.21
Financial Currency USD Current Ratio 5.54 Gross Margins 76.61 %
Industry Disp Medical Devices Number Of Analyst Opinions 12 Country United States
Float Shares 53 M Two Hundred Day Average 115.37 Enterprise Value 7 B
Price To Sales Trailing12 Months 21.83 Forward PE -130.80 Regular Market Volume 348798
Ebitda -80668000 Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.

Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.